Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register
- 1 July 2006
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (7) , 895-898
Abstract
Objective: To describe the occurrence of baseline comorbidity in subjects with active rheumatoid arthritis starting treatment with biological agents. Such data are necessary to interpret the reported occurrence of adverse events following treatment. Methods: Baseline comorbidity was recorded in a large national cohort of patients with rheumatoid arthritis newly starting biological agents. The distribution of the number and types of comorbidities is presented. Results: In all, 7818 patients treated with biological agents (infliximab 3332, etanercept 3302, adalimumab 1059, anakinra 132) were included in the analysis. Comorbidity was common, with 58% of patients having at least one comorbid condition and 25% having more than one. The most frequent comorbid conditions were hypertension, depression, peptic ulcer disease, and respiratory disease. Conclusions: In routine use, patients treated with biological agents have high levels of baseline comorbidity, which should influence the interpretation of reported adverse events.Keywords
This publication has 20 references indexed in Scilit:
- Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor AntagonistAnnals of Internal Medicine, 2003
- Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapyRheumatology, 2003
- Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agentsArthritis & Rheumatism, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanerceptArthritis & Rheumatism, 2002
- Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patientsArthritis & Rheumatism, 2002
- Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritidesArthritis & Rheumatism, 2001
- A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.2001
- Comorbidity in arthritis.1999
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995